March 22, 2022
A cancer research discovery made at the University Health Network and The Hospital for Sick Children has spurred a major pharmaceutical industry deal between Pfizer Inc. and Trillium Therapeutics
“Don’t Eat Me”. It’s a simple biological message whispered by crafty cancer cells to the immune system as they attempt to spread, grow and avoid destruction.
But the complex work to understand and control that signal which gives those dangerous cells the power to hide has taken decades of research to understand. Last year, the story took a new twist when it spurred pharmaceutical giant Pfizer Inc.’s acquisition of Trillium Therapeutics in a US$2.22 billion deal.
December 6, 2022
Drs. Heather Ross and Joseph Cafazzo are the winners of UHN's 19th annual Inventor of the Year Award.
The researchers are being recognized for their discovery leading to the commercialization of the Medly platform, a fit-in-your pocket companion for heart care powered by software and artificial intelligence developed at UHN.
Medly is also the basis of UHN new venture Medly Therapeutics, poised to bring heart care benefits to patients around the world.
February 24, 2022
Founded in 2012 based on UHN technology invented by Dr. Milos Popovic, Director at UHN’s KITE Research Institute, MyndTec Inc. is currently working to develop MyndMoveTM – a commercialized product that delivers electr...
June 22, 2022
Adela, based on the cutting-edge work of two scientists at the Princess Margaret Cancer Centre, raises US$60 million in financing A convenient blood test for cancer and other diseases could be on the horizon with Ad...
April 24, 2023
UHN tech ensures precise delivery of radiation during treatment and is now used world-wide
April 19, 2023
Adela's presentation at the American Association of Cancer Research (AACR) in April of 2023 focused on the ability of its genome-wide methylome enrichment platform, first discovered at UHN, to detect a broad set ...
September 22, 2021
“Congratulations to Lucid and FSD Pharma on taking this important step to accelerate potential treatment options for patients with multiple sclerosis based on technology developed at UHN. Working with our industry par...
%20(2).png)
November 18, 2021
Proceeds will fund the continued clinical development of CFI-400945, CFI-402257 and CFI-402411, the preclinical development of the Biologics and Cell Therapy platform. Financing led by Sino Biopharmaceutical and 3W Fu...
